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Abstract 
Background: Drugs that inhibit cyclooxygenase-2 (COX-2) while sparing cyclooxygenase-1 (COX-1) represent a new 
attractive therapeutic development and offer new perspective for further use of COX-2 inhibitors. Intention of this 
work is to develop safer, selective COX-2 inhibitors that do not produce harmful effects.
Results: A series of 55 tyrosine derivatives were designed for evaluation as selective COX-2 inhibitors and investi-
gated by in silico for their anti-inflammatory activities using C-Docker. The results of docking study showed that 35 
molecules were found to selectively inhibit the enzyme COX-2. These molecules formed stable π hydrophobic and 
additional van der Waals interactions in the active site side pocket of COX-2. The molecules selected from docking 
studies were examined through ADMET descriptors and Osiris property explorer to find its safety profile as well. The 
tyrosine derivatives containing toxic fragments were eliminated.
Conclusion: The results conclude that out of 55, 19 molecules possessed best binding energy (< −3.333 kcal/mol) 
and these molecules had more selective and safer COX-2 inhibitor profile compared to the standard celecoxib.
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Background
Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 
(COX-2) are two discrete isoforms of cyclooxygenase 
enzyme. These enzymes play a catalytic role in trans-
figuration of arachidonic acid to prostaglandins in the 
cyclic pathway of arachidonic acid [1, 2]. Prostaglandins 
(PGs) are involved in various pathophysiological condi-
tions such as inflammation, carcinogenesis, cardiovas-
cular activity etc. Generally, COX-2 is not detectable in 
most normal tissues, but it is induced by pro-inflamma-
tory cytokines, growth factors and carcinogens. This fact 
indicates the role of COX-2 in inflammation [3]. Rheu-
matoid synovium expression of COX-2 is up regulated in 
inflammatory tissues resulting in the production of pros-
taglandin precursors which ultimately gets converted 
into PGs [4].
Some of the coxib derivatives, Rofecoxib, Celecoxib, 
Etoricoxib and Valdecoxib are selective COX-2 inhibi-
tors that act by blocking COX-2 enzyme responsible for 
inflammation and pain [5]. Most of these coxib deriva-
tives have been voluntarily withdrawn from the world-
wide market due to safety concerns of an increased 
risk of cardiovascular events in patients. Due to greater 
therapeutic effect, Celecoxib is remaining in the market, 
even though it have a risk of serious and potentially fatal 
adverse cardiovascular thrombotic events, myocardial 
infarction and stroke [6].
Importantly, design of agents with higher anti-inflam-
matory potential and less side effects is one of the most 
challenging areas in the inflammation. On review of liter-
ature, researchers have proved anti-inflammatory effects 
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for dibromotyrosine derivatives [7]. In this concern, we 
searched for tyrosine scaffold from the natural sources 
since the biologically active natural compounds are com-
posed of very complex structures. This complexity makes 
the compounds extremely novel. The marine sponges 
such as Psammaplysilla purpurea and Ianthella basta 
are known to produce biogenetically related bromotyros-
ine derived secondary metabolites [8, 9]. These observa-
tions prompted us to design and develop analogue(s) of 
bromotyrosine derivatives which specifically inhibits 
COX-2 with improved biological activity. As part of this 
drug development, an effort has been made to develop 




A library of novel 55 tyrosine molecules were designed 
based on the SAR studies of known anti-inflammatory 
drugs. These molecules were generated with tyrosine 
as a basic skeleton. The 15 (R1) and 16 (R2) position of 
aromatic ring hydrogen was substituted with different 
electronegative groups such us, –I, –Br, –Cl and –NO2. 
Further, one hydrogen atom of –NH2 group in 14 (R3) 
position was replaced by –SO2CH3 group. The eighth 
position (R4) of phenolic –OH group hydrogen was 
replaced by diverse heterocyclic fragments (Fig.  1). The 
structures of these molecules were drawn in Hyperchem 
molecular modeling and visualization tool (version 7.5) 
and the energies were minimized using ADS. The mini-
mized ligands and proteins were saved in structure data 
(.sd) and.pdb format (Fig.  2) respectively for further 
studies.
Docking study
The docking study was performed using Accelyrs Dis-
covery Studio client version 2.5 software (Accelyrs Inc., 
http://www.accelrys.com). The X-ray crystallographic 
structure of COX-2 (PDB ID 3NT1) protein bound with 
naproxen was acquired from the protein data bank (PDB) 
at a resolution of 1.73  Å (Table  1). The active site was 
defined with a 8.500 (Å) radius around the bound inhibi-
tor which covered all the active site amino acids of the 
COX-2 protein. A grid-based molecular docking method, 
C-DOCKER algorithm was used to dock the small mole-
cules into the protein active site. The designed structures 
were submitted to CHARMm (Chemistry at HARvard 
Macromolecular Mechanics) force field for structure 
refinement. All water molecules, bound inhibitor and 
other hetero atoms were removed from the macromole-
cule and polar hydrogen atoms were added. The designed 
structures were also verified for its valency, missing 
hydrogen and any structural disorders like connectivity 
and bond orders. Energy minimization was carried out 
for all compounds using CHARMm force field to make 
stable conformation of protein with an energy gradient 
of 0.01  kcal/mol/A°. A final minimization of the ligand 
in the rigid receptor using non-softened potential was 
performed. For each final pose, the CHARMm energy 
(interaction energy plus ligand strain) and the interaction 
energy alone were calculated. The poses were sorted by 
CHARMm energy and the top scoring (most negative, 
thus favorable to binding) poses. The energy minimized 
individual proteins and the designed structures along Fig. 1 3D and 2D structure of energy minimized tyrosine derivatives
Fig. 2 Minimized secondary structure of a COX-2 (3NT1) b COX-1 (3KK6) c hERG protein (homology model)
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with the binding site sphere radius (Table 2; Fig. 3) and 
the X, Y and Z coordinates (Table 3) were submitted to 
the C-Docker job parameter. The docked conforma-
tion which had the lowest C-Docker energy was selected 
to analyze the mode of binding pattern. The C-Docker 
energy score, hydrogen bond and VDW interactions 
were visualized in C-Docker report and used for further 
analysis.
The potential fatal adverse effects viz ulcerogene-
city and cardiotoxicity were determined by C-Docker 
using the crystal structures of COX-1 in complex with 
celecoxib (3KK6:2.75  Å) and hERG_IFD_S-terfenadine_
model_1 [Homology model (HM)] (Table 1) which were 
chosen from the PDB and Schrodinger website respec-
tively. The binding sites of the COX-1 (3KK6) and hERG 
proteins were defined with the radii of 6.988 and 7.411 Ǻ 
respectively. The novelty of the final hits was confirmed 
using SciFinder [10] and PubChem [11] structure search 
tools.
Docking protocol validation
The validation of the docking protocol is essential to ana-
lyse the prediction ability of the proposed method [12]. 
In this study, validation is performed by two methods to 
verify whether our docking protocol is able to discrimi-
nate selective and non-selective COX-2 inhibitors. To 
start with, four native co-crystallised ligands of selec-
tive and non-selective COX-2 inhibitors were identified 
and kept as reference template. The structures of these 
ligands were drawn separately and its energies were 
minimized. RMSD values were calculated and analysed 
by redocking the energy minimised ligand on reference 
template by molecular overlay technique in ADS. In the 
second method, the structures of various selective and 
non-selective inhibitors were drawn and the potential 
energies of the molecules were minimized with the help 
of conjugated gradient algorithm. Further, these mol-
ecules were docked with the COX-2 (3NT1) protein to 
calculate the binding energies. The experimental IC50 
Table 1 Protein resolution and its stable conformational energy
a  Homology modeling




3NT1 High resolution structure of naproxen:COX-2 complex 1.73 −492,721 −500,025
3KK6 Crystal structure of COX-1 in complex with celecoxib 2.75 248,964,312.95 −34,200.97
HMa hERG IFD S terfenadine model 1 – −15,609 −21,445.6
Table 2 Binding sphere radius and X, Y and Z coordinate values of defined protein binding site
Protein PDB ID Binding sphere radius (Å) Coordinates (Å)
X Y Z
3NT1 8.50067 −40.406 −51.829 −22.502
3KK6 6.98804 −32.413 −51.829 −5.617
hERG_IFD_S−terfenadine_ 
model_1
7.41161 189.526 −0.442 40.737
Fig. 3 Binding site representation of proteins a COX-2 b COX-1 c hERG_IFD_S- terfenadine_model_1
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activity values of these molecules were compared with its 
corresponding predicted C-Docker energy values and the 
point plot is graphed to identify the correlation between 
the IC50 and C-Docker energy.
Toxicity study
ADMET descriptors
Most of the failure of drug candidates during clinical tri-
als is due to its poor pharmacokinetic and toxicity prop-
erties [13]. Hence, prediction of ADMET properties prior 
to expensive experimental procedures is considered to be 
essential for the selection of successful candidates. In this 
work, in silico ADMET studies were done using ADMET 
descriptors algorithm of ADS. This protocol uses the 
six pharmacokinetic parameters like Human Intestinal 
Absorption (HIA), Blood–Brain–Barrier (BBB) penetra-
tion, aqueous solubility, hepatotoxicity levels, cytochrome 
P450 2D6 inhibition and Plasma Protein Binding (PPB) to 
quantitatively predict the molecular properties of selected 
35 ligands.
Osiris property explorer
Toxicity risks (mutagenicity, tumorigenicity, skin irri-
tation, reproduction) and physicochemical properties 
(drug likeness and drug score) of the selected 35 tyros-
ine derivatives were calculated using OSIRIS Property 
Explorer (free web-based program). The drug likeness (d) 
was calculated with the following equation by summing 
up the scores of molecular fragments (Vi) and n indicates 
the number of molecular fragments [14].
The fragment list was created by shredding 3300 traded 
drug as well as 1500 commercially available chemicals.
The drug score (ds) combines drug-likeness, cLogP, 
logS, molecular weight and toxicity risks in one handy 
value that may be used to judge the compound’s overall 
potential to be qualified as a drug. This value was calcu-
lated by multiplying the contributions of individual prop-
erties with Eq. (1) [15].
ds is the drug score. si  are the contributions calculated 
directly from of cLogP, logS, molecular weight and drug-
likeness ti is the contribution taken from the four toxicity 
risk types via the Eq. (2) which describes a spline curve.
Results and discussion
Docking
The results of C-Docker protocol run were analysed. 
These results have provided essential information relat-
ing to the orientation of the tyrosine derivatives in the 
active site of proteins (3NT1, 3KK6, hERG).
Molecular docking
In this study, 35 drug-like hit compounds were selected 
from the designed 55 tyrosine derivatives based on 
their better binding affinity (–C-Docker energy) com-
pared to the standard celecoxib (Table 4). The active site 
was defined based on the bound inhibitor, naproxen, 
in a crystal structure of COX-2 (PDB code 3NT1). The 
important criteria considered in the selection of best hit 
compounds was binding modes, molecular interactions 
with the active site components and fitness scores. Evalu-
ation of the interaction pattern of tyrosine derivatives 
makes clear that the molecule 8 (Fig.  4) have six folds 
higher affinity (−78.7003) in the COX-2 active site com-
pared to standard celecoxib (17.3339). This interaction 















Table 3 C-Docker docking protocol parameters
Parameters Inputs
Input receptor ../Input/3NT1.dsv
Input ligands C:\Users\g\Desktop\all 55 new.sd




Random conformations dynamics 
steps
1000
Random conformations dynamics 
target temperature
1000
Include electrostatic interactions True
Orientations to refine 10
Maximum bad orientations 800
Orientation VDW energy threshold 300
Simulated annealing True
Heating steps 2000
Heating target temperature 700
Cooling steps 5000
Cooling target temperature 300
Force field CHARMm
Use full potential TRUE
Grid extension 8
Ligand partial charge method CHARMm
Random number seed 314,159
Final minimization Full potential
Random dynamics time step 0.002
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Molecule_8 −78.7003 4.96727 −74.2658 16.3263 −199.774 −155.629 3.78158 0.09694
Molecule_54 −46.1094 3.80434 9.73689 40.9916 −161.106 −129.460 5.45173 0.09737
Molecule_23 −45.4158 1.08668 −2.98987 44.0659 −177.976 −139.880 5.17214 0.09761
Molecule_6 −40.1233 1.50834 339.920 91.3010 −131.124 −106.360 1.62197 0.09667
Molecule_14 −38.0308 9.72515 −93.3437 6.78104 −128.448 −98.3557 2.48238 0.08123
Molecule_50 −32.9449 −3.8949 25.7593 47.7124 −133.414 −112.472 −0.05903 0.08110
Molecule_25 −29.4798 14.5849 14.0717 43.5888 −142.506 −118.107 1.45489 0.07719
Molecule_51 −28.5191 0.90861 32.0508 46.2969 −130.255 −100.616 2.08610 0.08137
Molecule_24 −28.4505 16.3299 534.240 568.860 −140.619 −104.274 3.04089 0.09149
Molecule_11 −26.1386 6.71301 61.7373 44.7827 −151.439 −136.499 −1.89433 0.09066
Molecule_10 −23.4787 21.0787 71.8921 63.5300 −157.857 −126.759 6.24669 0.09716
Molecule_20 −21.3714 17.7833 −17.3987 40.1040 −120.253 −99.3152 4.00568 0.09156
Molecule_21 −20.4346 21.4014 −55.1410 4.32287 −79.2812 −58.7042 1.69521 0.08615
Molecule_57 −15.0159 13.1286 28.7444 53.0095 −162.501 −128.173 8.40306 0.09806
Molecule_58 −12.0458 3.82902 −56.6613 20.5821 −152.031 −129.655 3.88633 0.09311
Molecule_7 −5.28412 22.9306 55,568.4 75,666.6 −150.99 −121.105 1.02490 0.09610
Molecule_67 −3.39829 11.7573 26.7832 42.2915 −123.539 −103.737 2.94580 0.09285
Molecule_59 −1.19358 14.2210 −89.0706 14.9038 −132.811 −104.716 3.23357 0.08664
Molecule_13 0.274143 19.9477 73.5331 48.1590 −130.355 −111.012 0.14158 0.09153
Molecule_17 0.957257 13.0669 −13.8560 6.29743 −42.2671 −25.9434 −1.71694 0.08943
Molecule_15 0.961175 18.3100 −37.7612 6.14656 −75.5862 −50.066 3.31430 0.08757
Molecule_102 4.763580 38.6705 −1.47768 6.52181 −20.0264 −13.5243 −6.95490 0.08871
Molecule_52 7.997040 16.8484 487.293 105.229 −155.493 −119.589 −0.16776 0.09978
Molecule_26 8.272020 21.8179 42.0749 38.5993 −138.631 −94.2976 2.46568 0.08678
Molecule_146 8.494660 38.3012 13.8468 6.52572 −12.4255 −7.32723 −7.01223 0.09203
Molecule_103 9.218700 41.1444 −0.67757 6.08668 −21.515 −13.0472 −4.12813 0.09382
Molecule_12 9.37307 23.8593 599.169 124.448 −133.207 −95.3196 −0.06212 0.09771
Molecule_99 10.0093 38.4689 10.9431 4.96463 −5.95502 0.97673 −4.40147 0.09965
Molecule_154 10.8974 42.4735 10.9119 7.15111 −16.5170 −5.14193 −5.71648 0.86146
Molecule_9 11.5098 24.9470 65.3320 46.7416 −120.920 −71.2045 2.39190 0.09569
Molecule_113 12.1402 41.6382 28,289.50 39,402.2 −136.929 −83.7555 2.70303 0.09185
Molecule_60 12.5198 19.1621 −13.2592 6.10851 −41.6039 −25.2553 −0.89500 0.08769
Molecule_115 12.5673 46.3928 −11.8405 6.12586 −44.0638 −23.2031 1.68847 0.09377
Molecule_141 12.8093 32.4320 −5.41508 4.20617 −29.7202 −17.6498 −0.35700 0.09705
Molecule_117 17.0983 38.6338 2021.79 2299.10 59.3405 96.7284 3.50862 0.09529
Celecoxib 17.33395 33.9253 13.8933 42.5446 −139.661 −117.986 6.21732 0.09936
Molecule_142 17.3898 38.1553 −79.2244 15.0265 −128.565 −93.4084 2.66973 0.09101
Molecule_100 17.9025 29.9299 6222.05 6373.98 −160.241 −112.801 1.91017 0.08234
Molecule_105 17.9411 39.9044 3.14311 5.19254 −19.9248 −12.5248 −3.32516 0.09908
Molecule_110 18.7239 44.9821 6.43866 5.82078 −15.4753 −6.75722 −1.88785 0.09904
Molecule_107 20.4115 36.5229 18.9587 5.76753 −11.5264 0.057840 −2.43628 0.09055
Molecule_98 20.7154 30.5548 −1.67995 5.36936 −21.3184 −9.82350 −1.23215 0.09869
Molecule_104 23.4169 41.1073 6.86145 4.83158 −23.4274 −2.71648 −5.74037 0.0969
Molecule_114 24.2130 49.8248 5.38092 5.21023 −12.5330 −4.10493 −4.12701 0.08961
Molecule_101 24.4073 38.7888 9.88176 16.3253 −17.7871 −5.53674 −3.82927 0.08234
Molecule_143 25.1057 38.8955 4.73240 5.43985 −23.7807 −9.70408 −2.10607 0.08908
Molecule_159 25.8484 38.2027 6.37157 5.98037 −34.4232 −3.90721 −5.13228 0.09613
Molecule_122 26.6459 39.9598 2.21425 6.49133 −34.9642 −14.2581 −6.04252 0.08389
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group in tyrosine moiety has formed two site point inter-
actions with the binding site residue of Arg120 and Tyr355 
residue. The 25th oxygen atom of the molecule produced 
one ligand point interaction with Arg120 residue which 
allows major interaction impact of the tyrosine deriva-
tives on catalytic domain of COX-2 protein. Besides, 
aromatic ring of the tyrosine skeleton make π-cationic 
interaction with Arg120. This created a stable conforma-
tion of the molecule 8 in the hydrophobic binding site of 
the COX-2 protein. This long hydrophobic channel cre-
ates cyclooxygenase active site that inhibits the inflam-
mation via non-steroidal anti-inflammatory drugs. This 
active site lengthen from the membrane binding domain 
to the region where the catalyzed chemical reaction takes 
place [16, 17]. In addition, R1 and R2 bromine substitution 
had generated VDW interaction with Val523 and Phe518 
that permitted the molecule 8 to access an additional side 
pocket which is a pre-requisite for COX-2 drug selectiv-
ity. This structural modification may be attributed to the 
interchange of valine at position of 523 in COX-2 for a 
relatively bulky isoleucine residue in COX-1 [5]. The 
substitution of 1, 3-thiazole ring at –OH (R4) position of 
tyrosine induced the VDW and electrostatic interactions 
with the active site amino acids. It created conducive 
chemical environment in the COX-2 binding site. Sub-
stitution of electronegative sulfonyl group at R3 posi-
tion enhanced the binding potential of the molecule by 
interacting with Ser353 (Figs.  5, 6). It is confirmed from 
this study that the COX-2 selectivity of the molecule 8 is 
higher than the standard celecoxib. The rest of 34 mol-
ecules were examined and found to have more stability 
when compared to the standard.
The COX-2 selectivity of the 55 tyrosine derivatives was 
compared with COX-1 enzyme. In this COX-1 docking 
study, the designed molecule had not created appropri-
ate conformation inside the active site of COX-1 enzyme 
due to the bulky amino acid residue Ilu523 and non-polar 
moieties of the His513. The VDW space of the tyrosine 
molecules in COX-1 chemical space of the active site is in 



















Molecule_111 29.4514 42.7783 38.9483 46.4718 −127.864 −82.6885 3.20745 0.08620
Molecule_118 30.2871 43.3848 13.8351 7.06563 −23.0209 −1.49548 −7.16945 0.08975
Molecule_144 31.0438 41.6663 16.4609 6.42745 −18.8412 4.78885 −6.92729 0.09901
Molecule_150 34.7730 46.4684 36.3206 7.23252 −7.94199 11.2902 −2.19893 0.08886
Molecule_112 35.1376 46.2887 8.39953 6.33198 −33.0042 −4.69838 −5.58198 0.09233
Molecule_151 35.3649 45.4588 33.7593 7.10073 −14.0113 18.3148 −3.51091 0.08832
Molecule_152 41.9392 45.3560 90.9266 30.9076 −12.7073 16.6751 −3.82475 0.09296
Fig. 4 Structure of molecule 8
Fig. 5 Interactions of molecule 8 with active site amino acids of 
COX-2 protein
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conflict with the receptor essential volume. This conflict 
creates steric repulsion between side chain amino acids of 
the COX-1 and designed molecules. It strongly evidenced 
that there is a large decrease in the affinity of the designed 
tyrosine derivatives with COX-1 when compared to the 
celecoxib. The above results proved that the tyrosine 
derivatives are more selective on COX-2 than COX-1.
Ulcerogenic interaction
The enzyme COX-1 played pivotal role in the mainte-
nance of mucosal integrity in the gastrointestinal tract. 
It is believed that the ulcerogenic effects of non-steroidal 
anti-inflammatory drugs is owing to exclusive inhibition 
of COX-1 [18]. The interaction between the designed 55 
tyrosine moiety and COX-1 protein aided to identify the 
ulcerogenicity level of designed molecules. The results of 
docking studies (C-Docker) revealed that the designed 
tyrosine derivatives exhibited more binding energy which 
was in contrast with the standard celecoxib (Table 5). The 
standard drug formed, one sigma-π, π-cationic and two 
hydrogen bond interaction with the Ile523, Arg120, Gln192 
and Lue352 amino acids respectively (Fig. 7). These bonds 
support the celecoxib to fit into the cavity of COX-1 
enzyme. On the other hand, the designed tyrosine 
derivatives formed hydrogen bonds with the Tyr385 and 
Ser530 (Fig.  8) and there is no other additional interac-
tion with the active site amino acids of COX-1 receptor. 
Also, the electro negative groups (-Br, -I) of the designed 
molecules forms intermolecular bumps which disfavors 
the binding capability of the molecules. These unstable 
conformations of the designed molecule prove their neg-
ligible ulcerogenic side effect.
hERG protein interaction studies
The hERG is the most critical channel involved in drug 
induced Torsade de Pointes (TdP) arrhythmias. Extra 
cellular application of celecoxib causes rapid suppres-
sion of hERG channels which induces the cardiac dis-
turbances [19]. Evaluation of spatial orientation of the 
designed molecule interactions with the hERG protein 
recognizes the cardiotoxicity level of molecules [20]. The 
results of docking studies indicated that among the 55 
designed molecules, 52 molecules possessed more inter-
action energy against the standard (Table 5). It revealed 
that these molecules are having less binding affinity to 
the active site residues of the hERG protein. In standard 
celecoxib, the benzyl ring creates π-π interaction with 
the Tyr652 (Fig. 9). This enables the celecoxib to fit well 
into the hydrophobic pocket of COX-2 protein. On con-
trary, tyrosine derivatives did not form any π-π interac-
tions and the extra volume of the electronegative group 
substitutions in the R1 and R2 positions which repulse 
the molecules to bind in the active site (Fig. 10). Hence, 
the cardiotoxicity of the designed molecules were less 
when compared to the celecoxib. The selected 35 tyros-
ine molecules demonstrated high COX-2 selectivity, less 
Fig. 6 2D Interactions view of molecule 8 with active site amino acids of COX-2 protein
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Table 5 C-Docker values for the tyrosine derivatives with COX-1 and hERG protein
Name of the molecule COX-1 hERG
C-Docker energy –C-Docker interaction energy C-Docker energy –C-Docker interaction energy
Molecule_11 11.1931 39.4964 25.6376 36.6014
Molecule_7 15.4566 35.6748 25.7715 38.8912
Molecule_102 18.612 45.7385 6.12591 32.7374
Molecule_99 22.7057 45.0127 13.8034 33.4137
Molecule_10 23.7368 49.2067 17.2666 37.8672
Molecule_113 25.291 51.6406 11.4752 37.2134
Molecule_14 25.5442 45.5213 27.0423 39.9337
Molecule_50 27.2685 42.4608 37.1187 35.2034
Molecule_54 27.9592 45.2948 30.1138 37.0948
Molecule_154 28.0068 48.3108 22.5487 37.1437
Molecule_103 28.5622 49.3350 12.6594 33.7937
Molecule_23 28.9051 51.4072 27.8294 36.9222
Molecule_146 29.7938 48.7906 12.7369 29.7554
Molecule_117 32.24 50.9400 17.502 35.4744
Molecule_122 32.4296 41.5757 23.1628 31.3608
Molecule_21 32.7128 54.7328 26.6071 40.1819
Molecule_8 33.0627 39.4668 36.4622 33.5932
Molecule_115 33.5042 53.2589 16.3142 35.3354
Molecule_105 33.9553 48.2822 20.7848 31.2565
Molecule_114 34.2029 54.9272 19.9584 37.415
Molecule_25 34.4117 51.3171 32.1083 41.2442
Molecule_100 34.7976 46.4333 21.2323 30.1093
Molecule_110 34.9249 53.1217 16.7253 34.8426
Molecule_6 35.033 45.8393 41.2549 36.2332
Molecule_26 35.2188 44.5275 43.3746 38.2527
Molecule_51 35.9835 42.5881 41.6024 38.3912
Molecule_107 36.0181 46.6087 21.6437 29.0359
Molecule_159 36.4927 43.0306 25.964 32.5955
Molecule_142 37.3162 49.1502 22.6982 30.9975
Molecule_141 37.8732 49.0256 23.9516 32.7221
Molecule_15 37.9714 43.6680 37.2577 34.7344
Molecule_58 38.0398 42.8592 43.586 36.3985
Molecule_13 39.4551 49.4952 35.9365 38.5156
Molecule_52 41.2608 41.016 48.0603 37.6181
Molecule_67 41.3861 43.4004 40.4953 37.1043
Molecule_59 41.5117 49.588 51.4686 44.477
Molecule_104 41.5637 48.3222 25.0942 32.4227
Molecule_101 42.6379 48.1987 25.8003 32.6898
Molecule_98 42.9202 48.7329 27.3695 33.4591
Molecule_143 43.1506 48.7602 26.4997 32.3527
Molecule_9 43.4413 49.4292 40.1671 35.6967
Molecule_20 44.4891 48.6384 45.1393 37.1212
Molecule_24 45.1278 54.9812 39.8631 37.5571
Molecule_12 45.21 49.8787 41.6676 37.8414
Molecule_111 45.9116 51.7703 27.1743 33.3161
Molecule_144 46.9694 46.4174 34.4717 35.0657
Molecule_112 47.1361 50.3979 32.8243 35.6348
Molecule_151 48.0494 53.3779 35.1662 37.0065
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COX-1 (ulcerogenic) and hERG (cardiotoxicity) bind-
ing affinity. Further, these molecules were examined by 
ADMET descriptors calculation and OSIRIS properties 
explorer.
Docking protocol validation
The results of RMSD values of redocked native co-crys-
tallized ligand of each PDB entry revealed that native 
ligand conformations including 3NT1 and best docked 
ligand conformation exactly binds in the experimental 
protein binding mode. In the docking study performed 
by first method, RMSD values of best docked confor-
mations ranged from 0.8436 to 1.7674 Å. According to 
validation protocol, RMSD values of best docked con-
formation should be ≤2.0 Å [21]. It represents that this 
docking protocol is able to find an appropriate binding 
mode. The designed 55 molecules were redocked into the 
active site of the COX-2 (3NT1) receptor and confirms 
that these docked molecules followed the similar binding 
method as in native co-crystallised ligand (Table 6).
In the second method, the selected docking proto-
col parameters accurately distinguished the selective 
and non-selective COX-2 inhibitors. It is illuminated 
by the docking results in which C-Docker energy of 
selective COX-2 inhibitors fall in the negative kcal/mol 
range and the non-selective inhibitors energies fall in 
Table 5 continued
Name of the molecule COX-1 hERG
C-Docker energy –C-Docker interaction energy C-Docker energy –C-Docker interaction energy
Molecule_150 48.0592 53.4856 29.3814 36.5024
Molecule_118 48.319 52.7029 29.5539 33.4975
Molecule_17 48.6628 48.8614 45.811 38.6698
Molecule_60 49.6967 49.4645 56.8447 44.3316
Molecule_152 52.4378 51.2126 40.7779 35.7427
Celecoxib 19.4457 51.7111 −0.642396 30.7255
Fig. 7 Celecoxib interaction map with the COX-1 protein a 2D view of non-bonded interactions b 3D interaction view
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Fig. 8 Tyrosine derivatives interaction map with the COX-1 protein a 2D view of non-bonded interactions b 3D interaction view of hERG protein 
interaction
Fig. 9 Standard celecoxib interaction map with the hERG protein a 2D view of non-bonded interactions b 3D interaction view
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the range of positive kcal/mol (Table  7). Additionally, 
the binding site (3NT1) analysis of the drug receptor 
complexes revealed that all the selective COX-2 inhibi-
tors formed π interaction with the active site amino 
acids which are major force for molecular recogni-
tion and join with hydrophobic interaction [22]. But, 
non-selective COX inhibitors formed hydrogen bond, 
VDW and electrostatic interactions only (Fig.  11). It 
clearly proves that the selective COX-2 inhibitors and 
designed 55 molecules possessed more selectivity com-
pared to the non-selective inhibitors. This proposed 
model predicted the correlation between C-Docker 
energy and the experimental IC50 value of the selective 
and non-selective inhibitors. The correlation coeffi-
cient was predicted to be 0.835 (r2) (Fig. 12). This cor-
relation strongly indicates that the docking protocol of 
this study possessed good predicting ability as well as 
it distinguishes the selective and non-selective COX-2 
inhibitors precisely.
Fig. 10 Tyrosine derivatives interaction map with the hERG protein a 2D view of non-bonded interactions b 3D interaction view
Table 6 Native co-crystallised ligands and  its respective 
PDB ID with its redocked RMSD values





Molecule 8 3NT1 1.0810
Table 7 C-Docker energy values of the selective and non-selective inhibitors
Selective COX-2 inhibitors C-Docker energy value (kcal/mol) Non-selective COX-2 inhibitors C-Docker  
energy value  
(kcal/mol)
Rofecoxib −19.0343 Diclofenac 5.45905
Valdecoxib −9.2766 Ketorolac 12.2429
Etoricoxib −3.32262 Aspirin 29.113
Naproxen 32.0361
Ibuprofen 39.7383
Page 12 of 19Puratchikody et al. Chemistry Central Journal  (2016) 10:24 
Toxicity
ADMET descriptors
In the present work, we have assessed ADMET (absorption, 
distribution, metabolism, excretion, and toxicity) properties 
of the 35 compounds which were selected from the dock-
ing report. ADMET descriptors were calculated to filter the 
poor tyrosine molecule with undesired pharmacokinetic 
and toxicity properties [23]. This step prevents wasting of 
time, chemicals as well as animal studies of tyrosine deriva-
tives. The pharmacokinetic profile of all the molecules was 
predicted by means of six pre-calculated ADMET models 
provided by ADS 2.5 software. The ADMET plot shows the 
95 and 99 % confidence ellipse for the HIA and BBB models 
(Fig. 13). The 95 % confidence ellipse represents the region 
Fig. 11 Interactions of selective and non-selective COX-2 inhibitors. a Rofecoxib b Aceclofenac
Fig. 12 Correlation point plot of C-Docker energy and the experimental activity (IC50) of the nonselective COX-2 inhibitors
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of chemical space with molecules having excellent absorp-
tion through cell membrane. According to this model, for a 
designed molecule to have an optimal cell permeability, it 
should follow the criteria of PSA < 140 Å2 and AlogP98 < 5) 
[24]. The selected 35 molecules have shown PSA < 140 Å2 
and AlogP98 < 5 which satisfied the criteria.
These selected molecules as well as standard celecoxib 
fall in the 95 and 99 % confidence ellipse for both HIA and 
BBB (Fig.  13). The HIA of the tyrosine derivatives ranges 
from 0 (good absorption) to 1 (moderate absorption) 
(Table  8). It indicates the good bioavailability of designed 
molecules to produce desired therapeutic effect. BBB pen-
etration of the designed molecules indicated undefined to 
low penetration, except the molecule 141. On the other 
hand, celecoxib exhibited moderate penetration to the BBB 
(Table 8). The aqueous solubility plays a vital role in the bio-
availability of the drug. The designed tyrosine derivatives 
have solubility in the range of 2 (low soluble) to 3 (soluble) 
as referred in Table  9. Further, the hepatotoxicity level of 
all the molecules were calculated, the molecules with liver 
toxic nature were filtered out. Similarly, all the molecules 
were found to be satisfactory with respect to CYP 450 2D6 
liver enzyme, suggesting that the tyrosine derivatives were 
non inhibitors of the metabolic enzyme. Finally, the PPB 
prediction denotes that all the designed molecules have 
binding  ≤90  % clearly revealing that the molecules have 
good bioavailability and are not likely to be highly bound to 
carrier proteins in the blood [25]. 
Osiris property explorer
The result of toxicity analysis of designed molecules 
showed low toxicity tendency except the molecules 
103 and 113. The drug-likeness value of standard and 
designed molecule exhibited the fragment content of 
the drug. If the drug-likeness value of designed mol-
ecules is increasing, then it has the same fragment 
content with existing drugs. Table  10 shows that the 
drug-likeness value of the tyrosine derivatives were 
higher than the standard celecoxib (−8.11), with the 
exception of 102, 103, 117, 141, 146 and 154 (−10.82 
to −11.92). This results predict that among 35, 29 
molecules exhibited same fragment content of the 
drugs. It confirms the drug likeness properties of these 
compounds.
The drug score value is the combination of solubil-
ity, molecular weight, logP, drug likeness and toxicity 
risk. It is used for evaluating the potential of the drug 
candidate. When the drug score is better, then the com-
pound is predictive to be a drug candidate [26]. The drug 
score value of standard celecoxib is found to contain 
Fig. 13 The 95 and 99 % confidence limit ellipses corresponding to the BBB and HIA models for tyrosine derivatives
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0.37. Finally 19 compounds which possessed drug score 
greater than the standard were shortlisted for further 
studies (Tables 11, 12).
Conclusion
In the current work, 55 tyrosine structural analogues 
on docking with COX-2, COX-1 and hERG revealed 





AlogP98 PSA 2D BBB  
level




CYP 2D6 PPB level
Molecule_6 0 2.843 109.513 4 −4.495 2 0 0 0
Molecule_8 0 2.634 105.719 4 −4.197 2 0 0 0
Molecule_9 0 1.862 118.273 4 −3.523 3 1 0 0
Molecule_10 1 1.317 129.534 4 −3.217 3 0 0 0
Molecule_11 0 2.402 120.689 4 −4.027 2 0 0 0
Molecule_12 0 1.852 120.774 4 −3.883 3 1 0 0
Molecule_13 0 2.419 118.273 4 −4.009 2 1 0 0
Molecule_14 1 1.804 132.035 4 −4.096 2 0 0 0
Molecule_15 0 3.047 94.458 3 −4.388 2 1 0 0
Molecule_17 0 2.503 109.513 4 −4.197 2 1 0 0
Molecule_20 0 1.522 118.273 4 −3.225 3 0 0 0
Molecule_21 1 0.976 129.534 4 −2.919 3 0 0 0
Molecule_23 0 2.068 120.774 4 −4.071 2 0 0 0
Molecule_24 0 2.078 118.273 4 −3.711 3 0 0 0
Molecule_25 1 1.464 132.035 4 −3.798 3 0 0 0
Molecule_26 0 2.707 94.458 3 −4.09 2 1 0 0
Molecule_50 0 2.599 105.719 4 −3.984 3 0 0 0
Molecule_51 0 2.186 116.98 4 −3.793 3 0 0 0
Molecule_54 0 0.613 116.198 4 −2.789 3 0 0 0
Molecule_58 0 2.259 105.719 3 −3.686 3 0 0 0
Molecule_67 0 1.354 116.98 4 −2.83 3 0 0 0
Molecule_99 0 3.245 90.972 3 −4.639 2 1 0 0
Molecule_102 0 1.505 108.662 3 −3.598 3 1 0 0
Molecule_103 0 2.59 99.817 3 −4.351 2 1 0 0
Molecule_113 0 1.164 108.662 3 −3.3 3 1 0 0
Molecule_115 0 2.256 99.902 3 −4.114 2 1 0 0
Molecule_117 0 1.652 111.163 4 −3.925 3 1 0 0
Molecule_141 0 3.937 73.586 2 −4.973 2 1 1 0
Molecule_146 0 0.801 95.326 3 −2.859 3 1 0 0
Molecule_154 0 2.18 99.817 3 −3.996 3 1 0 0
Molecule_7 0 2.193 120.774 4 −4.182 2 0 0 0
Molecule_52 1 1.753 128.241 4 −3.584 3 1 0 0
Molecule_57 0 3.409 94.458 3 −4.521 2 0 0 0
Molecule_59 0 1.846 116.98 4 −3.495 3 0 0 0
Molecule_60 1 1.413 128.241 4 −3.286 3 1 0 0
Celecoxib 0 4.428 77.75 2 −6.603 1 1 0 1
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that 35 molecules have more affinity at active site 
residues of COX-2 enzyme and less interaction with 
the other two proteins (COX-1, hERG) than standard 
celecoxib. This information proved to exhibit potential 
of high selective, less ulcerogenic and cardiotoxicity of 
the designed novel anti-inflammatory molecules. Fur-
ther, the result of ADMET and Osiris property explorer 
helped to eliminate 16 unwanted toxic fragments con-
tained tyrosine molecules. Finally, 19 hits with good 
pharmacokinetic parameter and negligible toxicity 
was proceeded for synthesis. Hence, it is concluded 
that the predicted parameters are exclusively used as a 
basis for the further design of tyrosine derivatives and 
understand the mechanism of COX-2 related enzy-
matic inhibition reactions. The next step of the potent 
safe anti-inflammatory drug identification involves the 
synthesis and biological evaluation of the selected mol-
ecules which are in progress.
Table 9 ADMET descriptor models
Name of the ADMET model Prediction levels
Human intestinal absorption 0 (Good absorption)
1 (Moderate absorption)
2 (Low absorption)
3 (Very low absorption)
Aqueous solubility 0 (Extremely low)














Plasma protein binding (PBB) 0 (Binding is <90 %)
1 (Binding is >90 %)
2 (Binding is >95 %
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Table 10 Toxicity of tyrosine derivatives and standard drug based on OSIRIS property explorer






Molecule_6 Green Green Green Green 1.88 0.63
Molecule_8 Green Green Green Green 2.25 0.62
Molecule_9 Green Green Green Green 1.83 0.60
Molecule_10 Green Green Green Green 2.46 0.66
Molecule_11 Green Green Green Green 0.87 0.53
Molecule_12 Green Green Green Green 2.46 0.67
Molecule_13 Green Green Green Green 2.61 0.65
Molecule_14 Green Green Green Green −2.08 0.39
Molecule_15 Green Green Green Green 2.03 0.54
Molecule_17 Green Green Green Green 4.74 0.54
Molecule_20 Green Green Green Green 4.69 0.50
Molecule_21 Green Green Green Green 5.29 0.55
Molecule_23 Green Green Green Green 5.54 0.57
Molecule_24 Green Green Green Green 5.43 0.53
Molecule_25 Green Green Green Green 0.74 0.48
Molecule_26 Green Green Green Green 4.88 0.45
Molecule_50 Green Green Green Green 2.34 0.45
Molecule_51 Green Green Green Green 1.46 0.60
Molecule_54 Green Green Green Green 1.77 0.59
Molecule_58 Green Green Green Green 4.31 0.51
Molecule_67 Green Green Green Green 2.39 0.46
Molecule_99 Green Green Green Green −0.06 0.46
Molecule_102 Green Green Green Green −10.82 0.39
Molecule_103 Green Yellow Red Green −15.1 0.18
Molecule_113 Green Green Red Green −7.79 0.32
Molecule_115 Green Green Green Green −7.28 0.33
Molecule_117 Green Green Green Green −11.92 0.33
Molecule_141 Green Green Green Green −17.18 0.34
Molecule_146 Green Green Green Green −11.29 0.35
Molecule_154 Green Green Green Green −8.91 0.31
Molecule_7 Green Green Green Green 3.47 0.70
Molecule_52 Green Green Green Green −2.79 0.21
Molecule_57 Green Green Green Green −0.83 0.49
Molecule_59 Green Green Green Green 4.36 0.52
Molecule_60 Green Green Green Green 2.39 0.29
Celecoxib Green Green Green Green −8.11 0.37
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Table 11 Details of shortlisted potent COX-2 inhibitors
Molecule 


























67 C15H16Cl N3O5S 385.823
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